Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05615415 · ClinicalTrials.gov registry record
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI
A clinical trial of Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection, sponsored by NYU Langone Health.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05615415 is a study of Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05615415, a study of Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this study is to develop PET/MR techniques for the diagnosis of neuropsychiatric post-acute sequelae (PASC) of SARS-CoV-2. The central hypothesis is that immunological and cerebrovascular dysfunction after acute SARS-CoV-2 infections mediate neuropsychiatric PASC (NP-PASC).
Conditions Studied
Interventions
- DRUG PET Tracer
- DRUG MRI Tracer
- DEVICE 3T PET/MRI
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05615415
The ClinicalTrials.gov registry entry for NCT05615415 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection appearing as the primary indexed condition, and to 3 interventions - of which PET Tracer is the first listed.
NCT05615415 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05615415 about?
NCT05615415 is a clinical study titled "Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI". The overarching goal of this study is to develop PET/MR techniques for the diagnosis of neuropsychiatric post-acute sequelae (PASC) of SARS-CoV-2. The central hypothesis is that immunological and cerebrovascular dysfunction after acute SARS-CoV-2 infections mediate neuropsychiatric PASC (NP-PASC).
What is the current status of trial NCT05615415?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2022-02-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05615415 study?
This clinical trial studies the following conditions: Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection.
What interventions are being tested in trial NCT05615415?
The interventions under investigation include: PET Tracer (DRUG), MRI Tracer (DRUG), 3T PET/MRI (DEVICE).
Who is sponsoring clinical trial NCT05615415?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05615415 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.